Entropy Neurodynamics LimitedASX: ENP

TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study

· Issued by Entropy Neurodynamics Limited

Filed with ASX · · 7 pages · English

Summary by 6ix AI

This shorter infusion period aims to evaluate whether it can maintain the positive clinical outcomes observed in the previous cohort while improving practicality and scalability. The trial is fully recruited, and topline results are expected by the end of the year. The CEO highlighted the significance of this milestone in addressing challenges in psychedelic medicine.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/trp-8803-60-minute-infusion-achieved-in-phase-2-bed-study

Release

ASX Announcement ASX : ENP 7 October 2026 First patient successfully completes 60-minute TRP-8803 infusion in Phase 2 Binge Eating Disorder study Melbourne, Australia – Entropy Neurodynamics Limited (‘Entropy Neurodynamics’ or the ‘Company’) (ASX: ENP), a clinical-stage biotechnology...

Entropy Neurodynamics Limited on 6ix

Earlier from Entropy Neurodynamics

Later from Entropy Neurodynamics

All Entropy Neurodynamics news releases